CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced the presentation of preclinical data using its proprietary antagonists of Toll-like receptors (TLR) 7 and 9 in mouse models of collagen-induced arthritis (CIA), a commonly used model for rheumatoid arthritis (RA). RA is an autoimmune disease characterized primarily by Th1-like immune responses. The presentation entitled “A Novel Class of DNA-Based TLR Antagonists Ameliorates Collagen-Induced Arthritis in Mice” (Poster #52) was made during the FASEB Summer Research Conference on Autoimmunity being held in Saxtons River, VT, July 14-19, 2007.
